Increasing reports show noninflammation underlying HCC, challenging our understanding of the roles of the immune system in hepatocarcinogenesis. By exploring a mouse model of hepatic tumor induced by hepatocyte-specific expression of the Hras12V oncogene without obvious inflammation, we found that the proportion of B cells, but not T cells, progressively and significantly decreased in 3, 5-month-old transgenic mice (Tg) compared with non-transgenic mice. Notably, the proportions of total and activated B and T cells all significantly decreased in 9-month-old Tg with multiple massive hepatic tumors. Together with the decreased B cell proportion, serum IgG1/2 also significantly decreased in 5, 9-month-old Tg. Interestingly, homozygous Tg showed significantly higher B cell proportion and IgG2 levels, accompanied by significantly lower incidences of liver nodules but not adenomas and carcinomas compared with heterozygous Tg. Treatment of Tg with PCI-32765, a potent Bruton's tyrosine kinase (BTK) inhibitor for suppressing B cell proliferation and activation, significantly decreased the B cell proportion and IgG2 levels, accompanied by a significantly higher incidence of liver nodules, but had no effects on adenoma and carcinoma. Treatment of Tg with insulin-like growth factor 1 (IGF-1) significantly increased the B cell proportion and IgG2 levels, accompanied by a significantly lower incidence of liver nodules and carcinoma, but had no effects on adenoma. Conclusively, B cells and IgG2 may play important roles in suppressing hepatic tumorigenesis, but not development. In addition, hepatocyte-specific expression of the ras oncogene may play roles in suppressing B cells, while developed hepatic tumors suppress both B and T cells.
these conditions, the interactions between cancer and the immune system remain to be elucidated.
Although anti-tumoral immune responses have been identified in many cancers, their roles in restricting hepatocarcinogenesis are not fully understood. 4 Specifically, increasing
reports have shown that a lack of inflammation underlying HCC adds challenges for understanding the roles of the immune system in hepatocarcinogenesis. 7 In addition, most studies performed to date have focused on the cell type with best antitumoral potential, i.e., CD8 1 T cells. By contrast, the role of humoral immunity in tumor immunosurveillance has been poorly explored. 8 In addition to the antibody-producing capacity, tumorinfiltrating B cells boost T-cell responses via stimulatory cytokines and chemokines, by serving as local antigen-presenting cells, and by forming tertiary lymphoid structures in mutual cooperation with T cells and dendritic cells. 9 In the classical dogma of tumor immunology, T-cell responses are considered to be good, whereas humoral responses oppose the latter and are consequently bad. Decades of experimental work with inbred mouse strains have supported this perspective. However, novel, clear data in the fields of autoimmunity and transplantation have demonstrated the extremely strong tissue damaging potential of B cells, especially when they interact with T cells. Thus, in terms of B cells, this dogma breaks down. 10 In the present study, we showed that B cells were significantly and progressively decreased with age and hepatic tumor development in Hras12V transgenic mice (Ras-Tg), a mouse model of hepatic tumor induced by hepatocyte-specific expression of the Hras12V oncogene without obvious inflammation. 11 Further investigation showed that reducing B cell proportion by PCI-32765 significantly increased the incidence of liver nodules but had no effects on adenoma and carcinoma. By contrast, increasing B cell proportion in response to insulin-like growth factor 1 (IGF-1) significantly decreased the incidence of liver nodules but had no effects on adenoma. Here, we demonstrate that B cells may play important roles in suppressing hepatic tumorigenesis but not in development in Ras-Tg.
Materials and Methods

Experimental animals, sampling and histopathological examination
Experimental animals and histopathological examination procedures for animal handling and tissue sampling were conducted in compliance with protocols approved by the Animal Care and Use Committee of Dalian Medical University. Hras12V transgenic mice (Ras-Tg) (C57BL/6 J genetic background), an animal model of hepatic tumor induced by hepatocyte-specific expression of the Hras12V oncogene, 11 and nontransgenic C57BL/6 J wild type mice (Non-Tg) were bred and housed in the Laboratory Animal Center of Dalian Medical University. Tissues from sacrificed male mice were removed and immediately flash-frozen in liquid nitrogen. The remaining tissue parts were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin using standard methods, and then subjected to histopathological examination. The morphological diagnosis confirmed that the tissues and mice were used for subsequent experimental procedures.
Animal treatment
Forty-five transgenic males at 3 months of age (3 M) were randomly divided into 4 groups. To reduce the number of B cells, PCI-32765 (Meilun Biotech) (50 mg kg 21 day
21
) was introduced into one group of Ras-Tg males (n 5 11), and another control group was treated with the same volume solvent (corn oil, 300 lL) (n 5 10) by daily intragastric administration. To increase the number of B cells, IGF-1 (Bioleaf Biotech) (312.5 mg kg 21 day
) was delivered to one group of Ras-Tg males (n 5 12), and another control group was treated with the same volume solvent (D-mannitol (M8140, Solarbio) 600 mL (300 mg L 21 )) (n 5 12) by daily intraperitoneal injection. The mice treated with PCI-32765, IGF-1, or the same volume solvent received treatment starting at 3 M and were sacrificed at 9 M. The body and liver weights, and the sizes and number of tumors were recorded, and the blood and tumors were collected for further analysis.
PCR and RT-qPCR
Total RNA was isolated from tissues using TRIzol reagent (DP405, Tiangen) and reverse-transcribed to single-stranded cDNA using a reverse transcription system (KR104, Tiangen). The qPCR was performed using Real Master Mix (SYBR Green, FP205, Tiangen) with an Applied Biosystems StepOnePlus Real-Time PCR System and PCR was performed using Premix Ex TaqTM HOT Start Version (R004, TaKaRa) on a TaKaRa PCR Thermal Cycler, according to the manufacturer's instructions. The primers used to detect the expression What's new? What role does the immune system play in non-inflammatory hepatocellular carcinoma (HCC)? In this transgenic mouse study, the authors found that the Hras12V oncogene expressing hepatocytes suppressed the number and activity of B cells. However, hepatic tumors suppressed the number and activity of both B and T cells. These findings indicate that hepatic tumors can evade the immune response. On the other hand, B cells, IgG2 and insulin-like growth factor (IGF-1) suppressed ras oncogene induced tumorigenesis, which suggests new therapeutic strategies for HCC. Further studies are needed to identify the underlying molecular mechanisms.
of target genes are shown in Supporting Information Table 1 . A separate analysis using primers for the detection of RPL35A or GAPDH was used as an internal control.
Flow cytometry
The peripheral blood was collected from mice by removal of the eye and placement in tubes containing EDTA anticoagulant. The tumor infiltrating cells were collected from hepatic tumor by homogenizing the tumor tissues after in situ perfusion to remove blood cells. Red blood cells were then eliminated by the addition of erythrocyte lytic solutions. For In vitro IGF-1 treatment, the extracted white blood cells were cultured in DMEM 1640 medium supplemented with 10% FBS and treated with IGF-1 (100 ng mL
21
) for 48 hrs. The above collected cells were washed with PBS and then incubated with fluorescently labeled mouse-specific antibodies or AF488-labeled ovalbumin (OVA, 5 mg mL 21 ) (Supporting Information Table 2 ) to detect subpopulations of immune cells or OVA-uptaking ability cells according to the manufacturer's instructions. After washing with PBS, the fluorescence intensity of 10,000 cells was analyzed by flow cytometry and analyzed using CELL Quest software with a FACScalibur (Becton Dickinson).
Immunohistochemistry
Sections were deparaffinized, rehydrated, retrieved the antigens, and then incubated with 1% H 2 O 2 in methanol for 15 min at room temperature to block endogenous peroxidase. After blocked with 5% bovine serum albumin, sections were incubated with primary and second antibodies (Supporting  Information Table 2) , and then an avidin-biotinylated peroxidase complex was applied with 3,3-diaminobenzidine as a peroxidase substrate. Immunoreactivity was visualized using diaminobenzidine. After that a light hematoxylin counterstain was applied.
Serum CRP, GGT, ASAT and ALAT examination
The serum levels of Gamma-glutamyltransferase (GGT), Alanine aminotransferase (ALAT), and Aspartate aminotransferase (ASAT) were detected using liver function test discs (MNCHIP, Tianjin, China). The serum levels of high sensitive C-reactive protein (HS-CRP) were detected using high sensitive C-Reactive protein detection kit (Nephelometry) and PA54 specific protein analyzer.
ELISA
The serum levels of IGF-1, IgG1 and IgG2 were determined using ELISA kits (Bioleaf Biotech) according to the manufacturer's instructions. The absorbance of the 96-well plates was read at 450 nm using an automated microplate reader (BioTek).
Statistical analysis
Data are presented as the means 6 SEM. The statistical significance of the differences between groups was determined by Student's t test or one-way ANOVA using Graphpad Prism 5 for the data following the Gaussian distribution. The immunohistochemistry data, obtaining by Image-Pro Plus (IPP) analysis and didn't follow a normal distribution, were analyzed using Mann-Whitney U test by SPSS (version 11.5; SPSS, Chicago, IL). p values < 0.05 were considered significant.
Results
Progressive hepatic tumorigenesis and development in Hras12V transgenic mice
Because of the frequent hyperactivation of Ras-dependent signal transduction pathways in human hepatocarcinogenesis, 12 Ras-Tg were produced by our group to investigate mechanisms associated with the ras oncogene-induced hepatocarcinogenesis. 11 The Hras12V oncogene is initiated by the Albumin enhancer/promoter and particularly expressed in hepatocytes that progressively developed hepatic dysplasia, nodule, adenoma, and carcinoma with age 11 (Figs. 1a and 1b). According to the histopathological diagnosis criteria described by Frith and Ward, 13 we approximately classified the hepatic alterations into two steps: tumorigenesis (nodule, <2 mm) and tumor development [adenoma (2-5 mm), carcinoma (>5 mm)], which clearly demonstrate the periodic pathological features. In particular, the incidences of hepatic alterations were mainly focused on nodules and adenoma in 5-month-old mice (5 M), indicating initial tumorigenesis and development. The alterations were the main focus in adenoma and carcinoma in 9 M, indicating the advanced development of tumors.
The liver weight was significantly and progressively increased with age, which may mainly result from the progressive liver alterations (Fig. 1c) . The Ras-Tg gain body weight at 5 M compared with 3 M, which may be due to the body growth and relatively increased liver alterations. However, body weight loss was observed in mice at 9 M compared with 5 M Ras-Tg, which may mainly result from the mass consumption resulting from multiple massive hepatic tumors (Fig. 1c) . Accordingly, the liver/body weight ratio was significantly increased only in 9 M Ras-Tg (Fig. 1d) .
As the inflammation has been recognized as an important factor in hepatic tumorigenesis and development, we checked the levels of serum inflammation markers in Ras-Tg. The results showed that there was no significant change in serum levels of HS-CRP and GGT between Non-Tg and Ras-Tg at 5 M and 9 M (Supporting Information Fig. 1 ). ALAT and ASAT were only significantly elevated in serum of 9 M RasTg compared to Non-Tg but not in 5 M mice, which may just result from the multiple hepatic tumors (Fig. 1e) . These data indicated that there was no significant inflammation in Ras-Tg. In addition, no significant pathological changes in other organs were detected (data not shown). These experiments indicate that the ras oncogene plays a dominant role in inducing hepatocarcinogenesis and development, although we could not exclude the possibility of the functions of Tumor Immunology and Microenvironment In addition, the tumor count dependence on the diameter (b), the liver and body weight (c), the liver/body weight ratio (d), and the serum Alanine aminotransferase (ALAT) and Aspartate aminotransferase (ASAT) (e) were further analyzed. Data are expressed as the mean 6 SEM (n512). *p < 0.05, **p < 0.01 and ***p < 0.001. M, months of age.
inflammation factors in tumor microenvironment. Therefore, the Hras12V transgenic mouse offers a particular disease model for investigating the roles of lymphocytes in hepatocarcinogenesis without obvious inflammation.
The B cell proportion is significantly decreased in Hras12V transgenic mice
To investigate whether the proportion of total and activated B cells varied in Ras-Tg, 3 M, 5 M, and 9 M males were examined. Interestingly, the proportions of total sIgM 1 B220
1 and sIgM 1 CD23 1 B cells in blood lymphocytes or in total white blood cells were significantly decreased in 3 M, 5 M, and 9 M Ras-Tg males compared with Non-Tg males (Figs. 2a and 2b, Supporting Information Table 3 ). Moreover, the proportion of blood B cells was also progressively and/or significantly decreased along with age in Ras-Tg males (Supporting Information Tables 4 and 5 ). Consistently, the proportion of OVA-uptaking B cells was also significantly decreased in 3 M and 9 M Ras-Tg males (Fig. 2c) . However, no significant change in the proportion of OVA 1 cells in gated B220
1 cells between Non-Tg and Ras-Tg indicates that the decreased function of B cells in Ras-Tg is mainly resulted from the decreased proportion of B cells (Fig. 2c) . Because IgG1 and IgG2 are the most abundant antibody subtypes produced by plasma B cells, we detected the concentrations of these two antibody subtypes to reflect the functions of B cells. Consistently, the serum concentrations of IgG1 and IgG2 were significantly decreased in 5 M and 9 M Ras-Tg males compared with Non-Tg males, although no changes in 3 M males were detected (Fig. 2d) .
For activated B cells, the proportions of activated CD19
1
CD69
1 and CD19 1 CD25 1 B cells in total white blood cells were significantly decreased in 5 M and 9 M RasTg males compared with Non-Tg males, although no changes in 3 M males were detected (Figs. 2e and 2f; Supporting Information Table 3 ). However, in blood lymphocytes, only the proportion of activated CD19
1
CD25
1 B cells was significantly decreased in 9 M Ras-Tg males compared with NonTg males (Supporting Information Table 3 ). The different counts between total white blood cells and blood lymphocytes supported the variation of blood cell composition in Ras-Tg. Interestingly, the decreased proportion of B cells was also apparent in the bloods of 4 M Ras-Tg females (Fig. 2g) . These experiments indicate that hepatic expression of the ras oncogene and hepatic tumor development may be the significant factors influencing the proportion and functions of blood B cells regardless of genders. Taken together, these results indicate that Ras-Tg have low proportion of B cells, which may contribute to hepatocarcinogenesis.
To exclude the possible influence of ectopic expression of the Hras12V transgene on lymphocytes, the expression of the transgene was detected in spleen, the largest lymphoid organ. Consistent with our previous reports, 11 the Hras12V transgene was expressed in peri-tumor tissues and at extremely higher levels in hepatic tumor tissues, but it was not expressed in spleen (Fig. 2h) . This finding indicates that the reduced proportion of B cells may not have resulted from ectopic expression of the Hras12V transgene in lymphocytes. In addition, the progressively decreased proportion of blood B cells with age and hepatocyte-specific expression levels of the ras oncogene indicate that the insertion site of the Hras12V transgene may not play a dominant role in these phenotypes. These findings indicate that hepatocyte-specific expression of the ras oncogene may play crucial roles in the suppression of B cells.
Total and activated T cells are significantly decreased in 9-month-old Hras12V transgenic mice carrying hepatic tumors
To investigate whether T lymphocytes change with hepatic tumorigenesis in Ras-Tg, the proportion of total and activated T cells in the blood of 3 M, 5 M and 9 M males was determined. In contrast to the decreased proportion of B cells, the proportion of CD3e 1 T cells in blood lymphocytes was significantly increased in the 3 M, 5 M and 9 M Ras-Tg males compared with the Non-Tg males (Figs. 3a and 3b) . Similarly, an increased proportion of T cells was also apparent in the bloods of 4 M Ras-Tg females (Fig. 3c) . However, the proportion of CD3e 1 T cells in total white blood cells was slightly decreased in 3 M and 5 M and significantly decreased in 9 M Ras-Tg males compared with Non-Tg males ( Fig. 3b ; Supporting Information Table 6 ). These trends were also observed in the subtypes of CD3e 1 CD4
1 and CD3e 1 CD8a 1 T cells (Supporting Information Table 6 ). Consistently, the activated CD3e 1 CD69 1 and CD3e
T cells in total white blood cells were slightly decreased in 3 M and 5 M and significantly decreased in 9 M Ras-Tg males compared with Non-Tg males ( Fig. 3e ; Supporting Information Table 6 ). In blood lymphocytes, activated CD3e 1 CD69 1 T cells were also significantly decreased in 9 M Ras-Tg males compared with Non-Tg males (Figs. 3d and 3e). In addition, contrast to the lower proportion of T cells, the proportion of regulatory T cells (CD4 1 Foxp3 1 ) was slightly increased in 9 M Ras-Tg compared to Non-Tg (Fig.  3g) . These findings indicate that the relatively increased proportion of blood T cells in lymphocytes is resulting from the decreased proportion of B cells. Moreover, the significantly decreased proportions of T and activated cells, and increased regulatory T cells in total white blood cells in 9 M but not in 3 M and 5 M Ras-Tg males indicate the significant suppressive roles of hepatic tumors on the proportion and activities of T cells.
Specific composition of tumor infiltrating immune cells and high levels of TIM-3 in the hepatic tumor tissues
As tumor infiltrating immune cells in tumor microenvironment has been recognized as crucial factors in tumor progression, we further investigated the composition of tumor infiltrating immune cells in the hepatic tumors of Ras-Tg. As expected, there existed appreciable quantity tumor-associated Tumor Immunology and Microenvironment (Fig. 4a) . Moreover, there were also appreciable quantity lymphocytes in the hepatic tumors (Figs. 4bd) . However, the composition of tumor infiltrating lymphocytes was much different compared to that in the blood. Notably, the T cells occupied the majority of lymphocytes and had low CD4 
CD19
1 CD25 1 (1.14 6 0.59%)) in the tumor. These data indicate that the specific composition of tumor infiltrating immune cells reflects the immunosuppressive microenvironment of the hepatic tumor, which may contribute to tumor progression.
In addition, as the expression of inhibitory checkpoint molecules in tumor tissue has been recognized as an important immune mechanism to evade the immune system, the levels of PD-1, PD-L1, CTLA-4, LAG-3 and TIM-3 were analyzed by immunohistochemical methods. The results showed that the levels of PD-1, PD-L1, CTLA-4 were too low to be detected in normal liver tissues of Non-Tg (Wt), hepatic pertumor normal liver tissues (HP) and hepatic tumor tissues (HT) of Ras-Tg (Supporting Information Fig. 2 ). LAG-3 was only significantly elevated in HP but not in HT compared to Wt (Fig. 4e) . Specially, TIM-3 was gradually and significantly up-regulated in the order of Wt, HP, and HT (Fig. 4e) . It indicates that ras oncogene elevated the levels of both LAG-3 and TIM-3 in normal hepatocytes, which may induce the immune tolerance and in turn promote hepatic tumorigenesis. However, significantly high level of TIM-3 may also contribute to the hepatic tumor progression.
B cell proportion and IgG2 concentrations negatively correlate to tumorigenesis in homozygous Hras12V transgenic mice
To investigate differences in the proportion of B and T cells between heterozygous and homozygous Ras-Tg, 9 M Ras-Tg males were examined. To our surprise, the proportion of blood sIgM 1 B220 1 B cells was significantly increased in homozygous compared with heterozygous males, although no difference was detected for the proportion of CD3e 1 T cells (Supporting Information Fig. 3a) . Consistently, the serum concentration of IgG2 was significantly increased in homozygotes, although no difference was detected for IgG1 (Supporting Information Fig. 3b) . However, the expression of the Hras12V transgene was significantly higher in HP and HT in homozygous compared with heterozygous mice (Supporting Information Fig. 3c ). Although the related causes remain to be elucidated, at least these data indicate that the insertion site of the transgene is not the main cause of the reduced proportion of B cells in Ras-Tg.
We further analyzed the incidence of tumorigenesis and development by tumor size (Supporting Information Fig. 3d) . Interestingly, the incidence of nodules <2 mm in diameter was significantly lower in homozygous compared with heterozygous males. In addition, although not statistically significant, the incidence of adenoma (2-5 mm in diameter) was also lower in homozygotes. However, the incidence of carcinoma (>5 mm in diameter) was slightly higher in homozygotes, potentially resulting from the higher expression levels of the Hras12V oncogene. Accordingly, the liver weight and liver/body weight ratio were significantly increased in homozygous compared with heterozygous males (Supporting Information Fig. 3e ). In addition, body weight significantly decreased in homozygous compared with heterozygous males because emaciation resulted from more massive hepatic tumors (Supporting Information Fig. 3e ). These data indicate that the expression levels of the Hras12V oncogene have a positive correlation to tumor development. Importantly, a direct negative correlation between the proportion of B cells and tumorigenesis was observed. Namely, a greater B cell proportion and a higher IgG2 concentration resulted in a lower incidence of nodules <2 mm diameters in homozygous in contrast to heterozygous males. In addition, the increased B cell proportion and IgG2 levels in homozygotes may result from the evoked adaptive immunity in response to the large tumor burdens. 14 
PCI-32765 reduces B cell proportion and increases hepatic nodules
PCI-32765 (Ibrutinib) is a potent, selective and orally bioavailable irreversible inhibitor of Bruton's tyrosine kinase (BTK) for suppressing B cell proliferation and activities. 15 To confirm the effectiveness of PCI-32765, Ras-Tg was treated at 3 M for 15 days. The results showed that PCI-32765 significantly reduced the proportions of B cells and OVA-uptaking B cells to about half of that in un-treated Ras-Tg (Supporting Information Fig. 4) and therefore confirmed the effectiveness of PCI-32765.
To investigate whether reduced B lymphocytes contribute to hepatic tumorigenesis, Ras-Tg was treated by PCI-32765 for 6 months aged from 3 M to 9 M. PCI-32765 treatment significantly reduced the proportion of blood B cells and the serum concentration of IgG2 but did not influence T cells and IgG1 (Figs. 5a and 5b) . As anticipated, along with the reduced B cell proportion and IgG2 concentration, the incidence of nodules (<2 mm) and total hepatic alterations was significantly increased, while there were no significant effects on the incidences of adenoma (2-5 mm) and carcinoma (>5 mm) (Figs. 5c and 5d ). These findings indicated that reduced B lymphocytes promote hepatic tumorigenesis but Tumor Immunology and Microenvironment not development. Consistently, PCI-32765 treatment had no significant effect on body weight, liver weight and the liver/ body weight ratio due to the lack of a significant effect on the incidence of large-sized tumors (Fig. 5e) .
IGF-1 increases B cell proportion and reduces hepatic nodules
Clinical studies have shown that the expression levels of growth hormone receptor (GHR) and IGF-1 are significantly down-regulated in HCC tissues. 16 Consistently, the mRNA levels of Ghr and Igf-1 were significantly decreased in HT compared with HP and Wt (Fig. 6a) . Accordingly, the serum concentration of IGF-1 was significantly decreased in Ras-Tg males compared with Non-Tg males (Fig. 6b) . IGF-1 has been reported to play important roles in stimulating the proliferation and activity of B cells. 17 These findings indicate that the reduced level of IGF-1 may contribute to the dramatically reduced proportion of blood B cells in Ras-Tg. To investigate whether IGF-1 could increase the proportion of B cells, which in turn influence hepatic tumorigenesis, Ras-Tg males were treated with IGF-1 for 6 months aged from 3 M to 9 M. IGF-1 treatment significantly increased the proportion of blood B cells and the serum concentration of IgG2 but did not influence the proportion of T cells and IgG1 levels (Figs. 6c and 6d) . As anticipated, along with the elevated proportion of blood B cells and IgG2 levels, the incidence of nodules (<2 mm) was significantly reduced in IGF-1-treated mice (Figs. 6e and 6f) , while there were no significant differences between the two groups in terms of the incidence of adenoma (2-5 mm) (Figs. 6e and 6f) . Interestingly, the incidence of carcinoma (>5 mm) was significantly reduced in IGF-1-treated males compared with the controls (Figs. 6e and f) . This result indicates that IGF-1 may play a role in suppressing hepatic tumor development. Accordingly, the total incidence of hepatic alterations was significantly reduced in IGF-1-treated males in comparison to the controls (Figs. 6e and 6f) . Consistently, the liver weights of IGF-1-treated males were slightly reduced compared with the controls, although this difference was not statistically significant. Accordingly, a significantly increased body weight and decreased liver/body weight ratio were observed in IGF-1-treated males compared with the controls (Fig. 6g) . The integrated data from the PCI-32765 treatment and the different phenotypes between homozygous and heterozygous males indicated that the elevated B cell proportion and IgG2 levels may function in repressing hepatic tumorigenesis in IGF-1-treated mice, regardless of the controversial and complex roles of IGF-1 in hepatic tumor development.
To check the possible direct stimulating effects of IGF-1 on the activity and proliferation of B cells, the in vitro investigation was performed. The results showed that IGF-1 treatment had no effect on the proportion, OVA-uptaking activity, or proliferation of blood B cells from Ras-Tg and non-Tg (Supporting Information Fig. 5 ). This result is consistent to the report that showed no response of normal B cells to IGF-1 treatment in vitro.
17 Therefore, the stimulating effects of IGF-1 on B cell may through an indirect way in vivo, such as increasing the B cell numbers by stimulating the proliferation of B lineage cells in bone marrow or spleen as the report suggested. 18 
Discussion
The role of B cells, antibodies, and T-B collaboration in antitumor immunity is controversial, with both positive and negative effects reported in animal models and clinical studies. Ras-Tg spontaneously develops hepatic tumors induced by hepatocyte-specifically expressed ras oncogene initiated by Albumin enhancer/promoter. 11 In this hepatic tumor model, the effects of hepatocytes-specific ras oncogene expression and hepatic tumors on immune systems and the influences of B and T cells and antibodies on hepatic tumorigenesis and development in a less inflammatory microenvironment could be studied. To the best of our knowledge, this is the first report to demonstrate that B cells and IgG2 may play important roles in hepatic tumorigenesis but not development. In addition, the hepatic expression of ras oncogene significantly decreased the proportion of B cells, and the hepatic tumors significantly suppressed proportions of B and T cells and activities. Further studies will reveal the underlying mechanisms.
The tumor microenvironment (TME) has been recognized to play a significant role in tumor progression. Specially, the inherent abilities of tumors to evade immune responses by inducing the immunosuppressive environment are the key points and the important targets for cancer immunotherapies. Among them, the expression of inhibitory checkpoint molecules in tumor has attracted significant attention. Interestingly, in the investigated inhibitory checkpoint molecules, only TIM-3 was extremely elevated in the hepatic tumors of Ras-Tg (Fig. 4e) . It indicates that TIM-3 may play crucial roles in suppressing immune cells. Accordingly, the specific composition of infiltrating immune cells in hepatic tumors also reflects the immune tolerance state in TME (Figs. 4a-d) . Notably, the accumulation of T cells and low CD4
1 /CD8 1 ratio, the very low proportion of B cells and existed population of sIgM 2 B220 1 cells, and the high proportion of TAMs in monocytes indicate the dysfunctions of immune cells. These evidences suggest the special immunosuppressive environment in ras oncogene induced hepatic tumor and offer new clues for further investigation.
The liver occupies the unique position between the gastrointestinal tract and the systemic venous system and is well known to be not only the metabolic center but also a regulatory lymphoid organ. Constant exposure to food antigens, bacterial products and potential pathogens through the mesenteric circulation, requires the liver to maintain tolerogenic capabilities while preserving the means to mount effective immune responses. The particular sinusoid system in liver harboring stellate cells, Kupffer cells, dendritic cells, T and B lymphocytes, natural killer cells and granulocytes, among others, ensures its roles in the adaptive/specific immune response. 19, 20 Interestingly, in the present study, we found that the proportion of B cells was significantly decreased as early as 3 M, with few liver alterations; it was extremely reduced at 9 M with multiple massive hepatic tumors in Ras-Tg (Figs. 1 and 2) . A decrease was also observed for T cells, although it was not statistically significant in 3 M and 5 M but was significant in 9 M Ras-Tg (Supporting Information Table 6 ). These trends were negatively correlated to the expression levels of the Hras12V transgene, which exhibited a gradual increase with age and was extremely increased in hepatic tumor tissues. 11 In particular, the Hras12V oncogene was highly expressed in hepatocytes initiated by the Albumin enhancer/promoter 11 (Fig. 2) . Considering that the liver plays principal roles in the assurance of the peripheral immune tolerance of the organism, which involves the tightly coupled regulation of proliferation, differentiation and survival of lymphocytes, especially the retardation of T and B lymphocytes, and that liver sinusoidal cells (LSECs) are fenestrated, thus facilitating the passage of cells and antigens between the sinusoids and the space of Disse, which is in contact with hepatocytes, 21 we therefore speculate that the expression of the ras oncogene may alter the status of hepatocytes, which in turn play roles in the proliferation and functions of lymphocytes, especially B cells. Accumulating evidence indicates that B lymphocytes exert complex functions in tumor immunity. On the one hand, B lymphocytes can inhibit tumor development through antibody generation, antigen presentation, tumor tissue interaction, and direct killing. On the other hand, compelling evidence suggests that B cells exert certain functions that suppress the immune response via several route, with regulatory B cells (Bregs) being the dominant element, 22 which have gained prominence in attenuating the immune response in malignant cancers. 23, 24 Moreover, B lymphocytes can work as inhibitory effectors by interacting with tumor tissues and certain types of lymphocytes, such as T cells, antigen-presenting cells (APCs), regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). 25 Therefore, the positive and negative effects of B lymphocytes on the immune system, which plays roles in oncogenesis and tumor progression, should be thoroughly elucidated. In the present study, we clearly demonstrated that the proportion of B cells was negatively correlated to the incidence of hepatic nodules but had no effect on the incidences of hepatic adenoma and carcinoma in Ras-Tg ( Figs. 1-6 ; Supporting Information  Fig. 4 ). These data indicate that B cells may play important roles in suppressing hepatic tumorigenesis but not development in a less inflammatory microenvironment.
In addition, the serum concentration of IgG2 was closely associated with the proportion of B cells and therefore had a negative correlation to the incidence of hepatic nodules but not to the incidence of hepatic adenoma and carcinoma in Ras-Tg ( Figs. 1-6 ; Supporting Information Fig. 4 ). These data indicate that IgG2 may also play important roles in the suppression of hepatic tumorigenesis. Indeed, it has been reported that the increased IgG2 values tend to correlate with prolonged breast patient survival but not IgG1, IgG3 and IgG4 levels. 26 Although the significant roles of IgG2 in the antitumor response remain to be investigated, the present study suggests that the IgG2 subclass may be more effective for tumor therapy.
Lower percentages of B and T helper lymphocytes in the peripheral blood of HCC patients suggest defective adaptive immunity.
14 Interestingly, in the present study, the simultaneously and significantly decreased total and activated T and B cells were only observed in 9 M Ras-Tg with multiple massive hepatic tumors, but not in 3 M and 5 M Ras-Tg with a few hepatic lesions (Figs. 1-3 ). This evidence indicates that the advanced hepatic tumor plays important roles in suppressing the proportions and activities of B and T cells. In addition, the best HCC marker, alpha-fetoprotein (AFP), has been suggested to play important roles in immune suppression in HCC patients. 21, 27 In the hepatic tumors of RasTg, the expression levels of AFP were also extremely increased (data not shown), which indicates that AFP may also be involved in immune suppression in transgenic mice. In addition, B cells seem to have few effects on the proportion of T cells. T cells were only decreased in aged mice with massive hepatic tumors, and altered proportion of B cells had no effects on the percentages of T cells (Figs. (3 and 5) and 6). Taken together, these findings indicate that hepatic tumors play roles in suppressing the proportions and functions of lymphocytes, which in turn favor immune evasion and thus promote tumor progression.
IGF-1 has been confirmed to be an inducer of many types of cancer. [28] [29] [30] IGF-1, a member of the insulin superfamily, has dose-dependent growth promoting and anabolic effects. The function of IGF-1 is regulated by IGF-1 receptor (IGF-1 R), a tyrosine kinase receptor that activates the PI3K/AKT and MAPK pathways. 31, 32 IGF-1 R expression is up-regulated in HCC tissues, and the use of an IGF-1 R inhibitor can reduce the growth and invasion of HCC cells. 33 However, clinical studies have demonstrated that the expression levels of IGF-1 are significantly lower in HCC tissues and serum of HCC patients, mainly because of the significantly downregulated growth hormone receptor (GHR), the upstream signals of IGF-1. 16, [34] [35] [36] Although some reports have shown that IGF-1 can promote the proliferation and migration of HCC cells, 37, 38 others have suggested that low serum IGF-1 levels are associated with insulin resistance and poor overall survival in HCC patients. 39 Therefore, the roles of IGF-1 in HCC progression remain to be elucidated. Intriguingly, the present study showed that treatment of Ras-Tg with IGF-1 significantly suppressed hepatic tumorigenesis and development (Fig. 6) . Although the detailed mechanisms remain to be detailed, the stimulating effect of IGF-1 on B cells may play important roles in suppressing hepatic tumorigenesis.
In conclusion, our work shows, for the first time, that B cells and IgG2 are negatively correlated to hepatic tumorigenesis, but not development. In particular, the expression of the ras oncogene in hepatocytes play crucial roles in the suppression of B cells, and hepatic tumors play important roles in suppressing proportions of lymphocytes and activities. Further investigation by exploring Ras-Tg will reveal the underlying mechanisms.
